<DOC>
	<DOCNO>NCT01313494</DOCNO>
	<brief_summary>The aim trial determine efficacy , safety tolerability 500 Âµg Roflumilast tablet daily patient COPD China , Hong Kong , Singapore .</brief_summary>
	<brief_title>A Chronic Obstructive Pulmonary Disease ( COPD ) Trial Investigating Roflumilast Safety Effectiveness China , Hong Kong Singapore :</brief_title>
	<detailed_description />
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Main Willingness sign write informed consent Chronic obstructive pulmonary disease ( COPD ) accord Global Initiative Chronic Obstructive Lung Disease ( GOLD ) guideline 2009 Chinese Malay Indian ethnicity History chronic obstructive pulmonary disease symptom least 12 month prior baseline visit V0 Forced expiratory volume first second/ Forced vital capacity ( FEV1/FVC ) ratio ( postbronchodilator ) &lt; 70 % Forced expiratory volume first second ( FEV1 ) ( postbronchodilator ) &lt; 50 % predict Former smoker ( define : smoking cessation least one year ago ) current smoker smoke history least 10 pack year Main Moderate severe COPD exacerbation and/or COPD exacerbation treat antibiotic stop V0 Lower respiratory tract infection resolve 4 week prior baseline visit V0 History asthma diagnosis patient &lt; 40 year age relevant lung disease COPD Current participation pulmonary rehabilitation program completion pulmonary rehabilitation program within 3 month precede baseline visit V0 Known alpha1antitrypsin deficiency</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Roflumilast</keyword>
	<keyword>FEV1</keyword>
	<keyword>China</keyword>
</DOC>